My name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, a graduate degree in Business Management from Universidad Andina Simon Bolivar, Quito, Ecuador, and the Ph.D. degree in computer applications from the University of Alicante, Spain.Disclosure: I collaborate professionally with Edgar Torres H, who is also an author on Seeking ...

ANDOVER, Mass., Feb. 27, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today issued additional information on the impact of the valuation allowance on deferred tax assets reported in the Company's fourth quarter financial results for the year ended December 31, 2025. As previously disclosed, in the fourth quarter of 2025, TransMedics released ...

Aster Capital Management DIFC Ltd cut its stake in shares of Stryker Corporation (NYSE:SYK – Free Report) by 44.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,491 shares of the medical technology company’s stock after selling 2,779 shares during the quarter. Stryker makes up about 0.7% of Aster Capital Management DIFC Ltd’s portfolio, making the stock its 28th largest position. Aster Capital Mana ...

Solventum (NYSE:SOLV) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Company ParticipantsAmy Wakeham - Senior Vice President of Investor Relations and External Finance CommunicationsBryan Hanson - CEODavid Roman - Managing Director in Global Investment Research DivisionDylan Finley - Director in Equity ResearchRick Wise - Managing Director in Medical Technology and SuppliesTravis Steed - Director in Medical Technology Equity ResearchVik Chopra - Director in Medical Technology Equity ResearchWayde McMil ...

Solventum (NYSE:SOLV) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Company ParticipantsAmy Wakeham - Senior Vice President of Investor Relations and External Finance CommunicationsBryan Hanson - CEODavid Roman - Managing Director in Global Investment Research DivisionDylan Finley - Director in Equity ResearchLeah Keiser - Equity Research AssociateRick Wise - Managing Director in Medical Technology and SuppliesTravis Steed - Director in Medical Technology Equity ResearchWayde McMillan - CFOConference ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - DexCom, Inc. has appointed Rick Osterloh to its Board of Directors, effective February 26, 2026, enhancing its leadership team with a seasoned technology executive [1][2]. Company Overview - DexCom is a leader in glucose biosensing technology, having pioneered advancements in this field for over 25 years, significantly transforming diabetes management and glucose tracking for users [6]. Leadership Appointment - Rick Osterloh brings over 20 years of experience in consumer hardware and product operations, currently serving as Senior Vice President at Google, where he oversees a unified group that includes Android, Google Play, Chrome, and various consumer devices [2][4]. - Osterloh's expertise includes innovation oversight, strategic transactions, and long-term planning, which aligns with DexCom's vision for product development [2][3]. Strategic Vision - The appointment of Osterloh is seen as a strategic move to leverage his insights into creating impactful products that integrate innovative technologies, which is crucial for advancing DexCom's mission to improve metabolic health globally [3][4].

Core Insights - Caris Life Sciences reported a significant revenue growth of 97% for the full year 2025, driven by strong performance in molecular profiling services [1] - The company expects full year 2026 revenue to be in the range of $1.0 billion to $1.02 billion, indicating a growth of approximately 23% to 26% compared to 2025 [1] Financial Highlights - Fourth Quarter 2025 total revenue was $292.9 million, a 125% increase from $129.9 million in Q4 2024, primarily due to a 199% growth in molecular profiling services revenue [1][3] - Full Year 2025 total revenue reached $812.0 million, up from $412.3 million in 2024, with molecular profiling services revenue growing by 120% to $766.7 million [1][3] - Gross margin improved to 75% in Q4 2025 from 54% in Q4 2024, and for the full year, it was 66%, up from 43% in 2024 [1][3] Operating Performance - The company completed approximately 52,700 clinical therapy selection cases in Q4 2025, a 20% increase year-over-year, and around 199,300 cases for the full year, a 22% increase [1] - Positive net cash provided by operating activities was $44.8 million in Q4 2025, compared to a net cash used of $38.9 million in Q4 2024, marking a 215% improvement [1][3] Future Outlook - Caris anticipates clinical therapy selection volume to grow approximately 20% in 2026 compared to 2025 [1] - The company announced a collaboration with Genentech to discover novel therapeutic targets in cancers with high unmet clinical need [1]

Market Overview - The market has been characterized by various concerns, including the impact of the Affordable Care Act (ACA), capital expenditures (CapEx), and weather conditions affecting procedures [1]. Company Focus - The company emphasizes executing effectively in a dynamic market environment, which includes driving commercial excellence to generate order growth and secure revenue growth [3]. - There is a strong focus on margin enhancements and productivity initiatives, alongside a commitment to innovation, which are seen as essential regardless of market conditions [3]. Conference Participation - The company has participated in the conference for three consecutive years since its spin-off, indicating a commitment to engaging with stakeholders and maintaining transparency [2].